

Mehul Dhorda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6151745/publications.pdf>

Version: 2024-02-01

69
papers

6,476
citations

159585

30
h-index

110387

64
g-index

77
all docs

77
docs citations

77
times ranked

5395
citing authors

#	ARTICLE	IF	CITATIONS
1	Spread of Artemisinin Resistance in <i>Plasmodium falciparum</i> Malaria. <i>New England Journal of Medicine</i> , 2014, 371, 411-423.	27.0	1,753
2	Genetic architecture of artemisinin-resistant <i>Plasmodium falciparum</i> . <i>Nature Genetics</i> , 2015, 47, 226-234.	21.4	515
3	The spread of artemisinin-resistant <i>Plasmodium falciparum</i> in the Greater Mekong subregion: a molecular epidemiology observational study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 491-497.	9.1	371
4	Spread of artemisinin-resistant <i>Plasmodium falciparum</i> in Myanmar: a cross-sectional survey of the K13 molecular marker. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 415-421.	9.1	363
5	Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. <i>Science</i> , 2015, 347, 431-435.	12.6	362
6	Determinants of dihydroartemisinin-piperaquine treatment failure in <i>Plasmodium falciparum</i> malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 952-961.	9.1	252
7	Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 943-951.	9.1	219
8	Polymorphisms in <i>Plasmodium falciparum</i> Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for <i>P. falciparum</i> Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 91, 833-843.	1.4	204
9	Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated <i>Plasmodium falciparum</i> malaria: a multicentre, open-label, randomised clinical trial. <i>Lancet</i> , The, 2020, 395, 1345-1360.	13.7	182
10	The epidemiology of subclinical malaria infections in South-East Asia: findings from cross-sectional surveys in Thailand-Myanmar border areas, Cambodia, and Vietnam. <i>Malaria Journal</i> , 2015, 14, 381.	2.3	163
11	Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on <i>Plasmodium falciparum</i> malaria in Eastern Myanmar: an observational study of a regional elimination programme. <i>Lancet</i> , The, 2018, 391, 1916-1926.	13.7	131
12	Numerical Distributions of Parasite Densities During Asymptomatic Malaria. <i>Journal of Infectious Diseases</i> , 2016, 213, 1322-1329.	4.0	108
13	Short-course primaquine for the radical cure of <i>Plasmodium vivax</i> malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. <i>Lancet</i> , The, 2019, 394, 929-938.	13.7	106
14	The impact of targeted malaria elimination with mass drug administrations on <i>falciparum</i> malaria in Southeast Asia: A cluster randomised trial. <i>PLoS Medicine</i> , 2019, 16, e1002745.	8.4	105
15	Artemisinin resistance without p _{fk} elch13 mutations in <i>Plasmodium falciparum</i> isolates from Cambodia. <i>Malaria Journal</i> , 2017, 16, 195.	2.3	99
16	Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated <i>Plasmodium falciparum</i> malaria: an open-label, randomised, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 762-769.	9.1	96
17	Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1470-1480.	9.1	94
18	Plasmepsin II copy number accounts for bimodal piperaquine resistance among Cambodian <i>Plasmodium falciparum</i> . <i>Nature Communications</i> , 2018, 9, 1769.	12.8	85

#	ARTICLE	IF	CITATIONS
19	Host immunity to <i>Plasmodium falciparum</i> and the assessment of emerging artemisinin resistance in a multinational cohort. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3515-3520.	7.1	78
20	Mapping imported malaria in Bangladesh using parasite genetic and human mobility data. ELife, 2019, 8, .	6.0	78
21	Triple Artemisinin-Based Combination Therapies for Malaria – A New Paradigm?. Trends in Parasitology, 2021, 37, 15-24.	3.3	67
22	Persistent <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> infections in a western Cambodian population: implications for prevention, treatment and elimination strategies. Malaria Journal, 2016, 15, 181.	2.3	54
23	Genetic surveillance in the Greater Mekong subregion and South Asia to support malaria control and elimination. ELife, 2021, 10, .	6.0	53
24	Computer-Automated Malaria Diagnosis and Quantitation Using Convolutional Neural Networks. , 2017, , .		52
25	Artemisinin and multidrug-resistant <i>Plasmodium falciparum</i> – a threat for malaria control and elimination. Current Opinion in Infectious Diseases, 2021, 34, 432-439.	3.1	51
26	A Controlled Trial of Mass Drug Administration to Interrupt Transmission of Multidrug-Resistant <i>Falciparum</i> Malaria in Cambodian Villages. Clinical Infectious Diseases, 2018, 67, 817-826.	5.8	48
27	An inventory of supranational antimicrobial resistance surveillance networks involving low- and middle-income countries since 2000. Journal of Antimicrobial Chemotherapy, 2018, 73, 1737-1749.	3.0	47
28	Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study. Malaria Journal, 2016, 15, 185.	2.3	43
29	Pharmacokinetic Properties of Artemether, Dihydroartemisinin, Lumefantrine, and Quinine in Pregnant Women with Uncomplicated <i>Plasmodium falciparum</i> Malaria in Uganda. Antimicrobial Agents and Chemotherapy, 2013, 57, 5096-5103.	3.2	41
30	Submicroscopic <i>Plasmodium</i> prevalence in relation to malaria incidence in 20 villages in western Cambodia. Malaria Journal, 2017, 16, 56.	2.3	40
31	Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated <i>Plasmodium falciparum</i> malaria in Uganda. Malaria Journal, 2012, 11, 293.	2.3	38
32	Artemisinin resistance in the malaria parasite, <i>Plasmodium falciparum</i> , originates from its initial transcriptional response. Communications Biology, 2022, 5, 274.	4.4	33
33	Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated <i>Plasmodium falciparum</i> malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial. Malaria Journal, 2013, 12, 251.	2.3	30
34	Efficacy of fixed-dose combination artesunate-amodiaquine versus artemether-lumefantrine for uncomplicated childhood <i>Plasmodium falciparum</i> malaria in Democratic Republic of Congo: a randomized non-inferiority trial. Malaria Journal, 2012, 11, 174.	2.3	28
35	Effectiveness and safety of 3 and 5-day courses of artemether+lumefantrine for the treatment of uncomplicated <i>falciparum</i> malaria in an area of emerging artemisinin resistance in Myanmar. Malaria Journal, 2018, 17, 258.	2.3	27
36	Triple therapy with artemether+lumefantrine plus amodiaquine versus artemether+lumefantrine alone for artemisinin-resistant, uncomplicated <i>falciparum</i> malaria: an open-label, randomised, multicentre trial. Lancet Infectious Diseases, The, 2022, 22, 867-878.	9.1	27

#	ARTICLE	IF	CITATIONS
37	Artemisinin Resistance and Stage Dependency of Parasite Clearance in Falciparum Malaria. <i>Journal of Infectious Diseases</i> , 2019, 219, 1483-1489.	4.0	25
38	Prevalence Study of Yaws in the Democratic Republic of Congo Using the Lot Quality Assurance Sampling Method. <i>PLoS ONE</i> , 2009, 4, e6338.	2.5	24
39	Performance of a Histidine-Rich Protein 2 Rapid Diagnostic Test, Paracheck PfA [®] , for Detection of Malaria Infections in Ugandan Pregnant Women. <i>American Journal of Tropical Medicine and Hygiene</i> , 2012, 86, 93-95.	1.4	24
40	Defining the next generation of Plasmodium vivax diagnostic tests for control and elimination: Target product profiles. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005516.	3.0	24
41	Population pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3033-3040.	3.0	22
42	History of malaria treatment as a predictor of subsequent subclinical parasitaemia: a cross-sectional survey and malaria case records from three villages in Pailin, western Cambodia. <i>Malaria Journal</i> , 2016, 15, 240.	2.3	21
43	Contribution of Functional Antimalarial Immunity to Measures of Parasite Clearance in Therapeutic Efficacy Studies of Artemisinin Derivatives. <i>Journal of Infectious Diseases</i> , 2019, 220, 1178-1187.	4.0	21
44	Performance of a fully automated system on a WHO malaria microscopy evaluation slide set. <i>Malaria Journal</i> , 2021, 20, 110.	2.3	21
45	Evolution of Multidrug Resistance in Plasmodium falciparum: a Longitudinal Study of Genetic Resistance Markers in the Greater Mekong Subregion. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0112121.	3.2	21
46	Arterolaneâ€“piperazineâ€“mefloquine versus arterolaneâ€“piperazine and artemetherâ€“lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1395-1406.	9.1	20
47	A comprehensive RNA handling and transcriptomics guide for high-throughput processing of Plasmodium blood-stage samples. <i>Malaria Journal</i> , 2020, 19, 363.	2.3	19
48	Artemether-lumefantrine to treat malaria in pregnancy is associated with reduced placental haemozoin deposition compared to quinine in a randomized controlled trial. <i>Malaria Journal</i> , 2012, 11, 150.	2.3	17
49	Deploying triple artemisinin-based combination therapy (TACT) for malaria treatment in Africa: ethical and practical considerations. <i>Malaria Journal</i> , 2021, 20, 119.	2.3	17
50	Transmission of Plasmodium vivax in South-Western Uganda: Report of Three Cases in Pregnant Women. <i>PLoS ONE</i> , 2011, 6, e19801.	2.5	17
51	Mapping genetic markers of artemisinin resistance in Plasmodium falciparum malaria in Asia: a systematic review and spatiotemporal analysis. <i>Lancet Microbe</i> , The, 2022, 3, e184-e192.	7.3	16
52	Field evaluation of the diagnostic performance of EasyScan GO: a digital malaria microscopy device based on machine-learning. <i>Malaria Journal</i> , 2022, 21, 122.	2.3	15
53	Optimal health and disease management using spatial uncertainty: a geographic characterization of emergent artemisinin-resistant Plasmodium falciparum distributions in Southeast Asia. <i>International Journal of Health Geographics</i> , 2016, 15, 37.	2.5	13
54	Towards harmonization of microscopy methods for malaria clinical research studies. <i>Malaria Journal</i> , 2020, 19, 324.	2.3	13

#	ARTICLE	IF	CITATIONS
55	Association between Subclinical Malaria Infection and Inflammatory Host Response in a Pre-Elimination Setting. PLoS ONE, 2016, 11, e0158656.	2.5	13
56	Abundance of megalin and Dab2 is reduced in syncytiotrophoblast during placental malaria, which may contribute to low birth weight. Scientific Reports, 2016, 6, 24508.	3.3	11
57	Optimizing bulk segregant analysis of drug resistance using Plasmodium falciparum genetic crosses conducted in humanized mice. IScience, 2022, 25, 104095.	4.1	8
58	To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?. PLoS ONE, 2021, 16, e0256567.	2.5	7
59	Mass drug administrations with dihydroartemisinin-piperazine and single low dose primaquine to eliminate Plasmodium falciparum have only a transient impact on Plasmodium vivax: Findings from randomised controlled trials. PLoS ONE, 2020, 15, e0228190.	2.5	6
60	Fully-automated patient-level malaria assessment on field-prepared thin blood film microscopy images. , 2019, , .		5
61	Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; protocol for a randomised, placebo-controlled prophylaxis study (COPCOV). Wellcome Open Research, 0, 5, 241.	1.8	5
62	A novel field-based molecular assay to detect validated artemisinin-resistant k13 mutants. Malaria Journal, 2018, 17, 175.	2.3	4
63	Polymorphisms in Pvkelch12 and gene amplification of Pvplasmepsin4 in Plasmodium vivax from Thailand, Lao PDR and Cambodia. Malaria Journal, 2019, 18, 114.	2.3	4
64	The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of Plasmodium vivax infections: a randomized, controlled trial in Lao PDR. Malaria Journal, 2020, 19, 4.	2.3	4
65	A Systematic Literature Review of Microscopy Methods Reported in Malaria Clinical Trials. American Journal of Tropical Medicine and Hygiene, 2021, 104, 836-841.	1.4	4
66	Ethical, Regulatory and Market related aspects of Deploying Triple Artemisinin-Based Combination Therapies for Malaria treatment in Africa: A study protocol.. Wellcome Open Research, 2021, 6, 75.	1.8	4
67	Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study. Frontiers in Cellular and Infection Microbiology, 2022, 12, 804470.	3.9	1
68	Comparison of antibody responses and parasite clearance in artemisinin therapeutic efficacy studies in Democratic Republic of Congo and Asia. Journal of Infectious Diseases, 0, , .	4.0	1
69	Highlights 2020: framing health stories. Lancet, The, 2020, 396, 1957-1971.	13.7	0